Δ9-THC-induced cognitive deficits in mice are reversed by the GABAA antagonist bicuculline

Psychopharmacology

Volumn 178, Issue 2-3, 2005, Pages 317-327

  Varvel, S A ^a   Anum, E ^a   Niyuhire, F ^a   Wise, L E ^a   Lichtman, A H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bicuculline; Cannabinoid; CB1 receptor; GABA; GABAergic; Morris water maze; SR 141716; THC; Working memory

Indexed keywords

3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; BICUCULLINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; MUSCIMOL; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; GABAERGIC SYSTEM; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WILD TYPE; WORKING MEMORY;

ANIMALS; BACLOFEN; BICUCULLINE; BRAIN; MALE; MARIJUANA ABUSE; MAZE LEARNING; MEMORY, SHORT-TERM; MENTAL RECALL; MICE; MICE, INBRED C57BL; MUSCIMOL; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GABA-A; RECEPTORS, GABA-B; TETRAHYDROCANNABINOL;

EID: 15044355640     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1988-2     Document Type: Article

References (28)

1. Coull MA, Johnston AT, Pertwee RG, Davies SN (1997) Action of delta-9-tetrahydrocannabinol on GABA(A) receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. Neuropharmacology 36:1387
2. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371
3. Egashira N, Mishima K, Iwasaki K, Fujiwara M (2002) Intracerebral microinjections of delta 9-tetrahydrocannabinol: search for the impairment of spatial memory in the eight-arm radial maze in rats. Brain Res 952:239
4. Ferraro L, Tomasini M, Cassano T, Bebe B, Siniscalchi A, O'Connor W, Magee P, Tanganelli S, Cuomo V, Antonelli T (2001) Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J Neurosci Res 66:298
5. Hajos N, Freund T (2002) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121:73
6. Hajos N, Katona I, Naiem S, MacKie K, Ledent C, Mody I, Freund T (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12:3239
7. Hoffman AF, Lupica CR (2000) Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20:2470
8. Irving AJ, Coutts AA, Harvey J, Rae MG, Mackie K, Bewick GS, Pertwee RG (2000) Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience 98:253 (in process citation)
9. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544
10. Kirby MT, Hampson RE, Deadwyler SA (2000) Cannabinoid receptor activation in CA1 pyramidal cells in adult rat hippocampus. Brain Res 863:120
11. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126:125
12. Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119:282
13. Mallet PE, Beninger RJ (1998) The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta-9- tetrahydrocannabinol or anandamide. Psychopharmacology 140:11
14. Maneuf Y, Crossman A, Brotchie J (1996) Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 22:382
15. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213
16. Mogil JS, Grisel JE (1998) Transgenic studies of pain. Pain 77:107
17. Nelson RJ, Young KA (1998) Behavior in mice with targeted disruption of single genes. Neurosci Biobehav Rev 22:453
18. Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729
19. 9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 27:1265
20. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 40:581
21. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa G, Devoto P (2002) D9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948:155
22. Romero J, de Miguel R, Ramos JA, Fernandez-Ruiz JJ (1998) The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci 62:351
23. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93:969
24. Varvel SA, Lichtman AH (2002) Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301:915
25. Varvel SA, Hamm RJ, Martin BR, Lichtman AH (2001) Differential effects of delta9-THC on spatial reference and working memory in mice. Psychopharmacology 157:142
26. 9-tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol 250:205
27. Wilson RI, Kunos G, Nicoll RA (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31:453
28. Zarrindast M, Bakhsha A, Rostami P, Shafaghi B (2002) Effects of intrahippocampal injection of GABAergic drugs on memory retention of passive avoidance learning in rats. J Psychopharmacol 16:313